Real world evidence provides clinical insights on tissue agnostic approvals of therapies

Authors:

George Sledge, Takayuki Yoshino, Joanne Xiu, Anthony Helmstetter, Sergey Klimov, Brady Gilg, Matthew Oberley, Milan Radovich, Jim Abraham, David Spetzler

Conclusions

  • TA indications are common, with one patient in every five tested being a candidate for TA therapy; however, TA frequency varies tremendously across cancer types.
  • Response durations (as measured by TOT) may not be tissue agnostic.
  • Some TA approvals (e.g., TMB-H) extend beyond the initial study populations. RWE may extend TA indications to other drugs in the same class.
Download Publication